Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L)1xVEGF-A bispecifics are more effective than traditional ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

In draft guidance, the agency has said that while Keytruda (pembrolizumab) added to chemotherapy is more effective than chemo alone. Its long-term benefits are uncertain. Moreover, NICE says there ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the ... with considerable side effects that forced a change in dosing ...

At the conference, Merck revealed findings from the KeyNOTE-522 study, which assessed the effectiveness of Keytruda combined ...

Lastly, the growing success of Keytruda has increased the firm's dependence on the drug for growth, which could become problematic if any side effects show up or new therapies emerge quickly in ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Padcev may be given alone or in combination with pembrolizumab (Keytruda). In Padcev clinical trials, the more common side effects differed depending on the treatment received. These are just a ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...